HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 11-21-2005, 11:55 AM   #1
Rich
Guest
 
Posts: n/a
implications for BC?

http://www.docguide.com/news/content...2570C0004A7FEE

Early research that demonstrated frequent loss of PTEN and anti-tumor activity induced with mTOR inhibition led Dr. Oza and colleagues to examine temsirolimus in women with endometrial cancer.

The research team evaluated a cohort of women with recurrent or metastatic endometrial cancer who had not received chemotherapy but had been treated with up to one prior line of hormonal therapy. The 18 women received temsirolimus at a dose of 25 mg weekly for a median of 24 weeks.

Results show that 31% of 16 evaluable women had a confirmed partial response; 63% had stable disease as best response; and 6% had progressive disease.

"It's very encouraging to see such a high level of activity at this early stage," Dr. Oza said. "The results are equivalent to those of currently used cytotoxic chemotherapy. It's really a stunning result."
  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 07:26 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter